Results 221 to 230 of about 89,048 (269)

Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up. [PDF]

Hemasphere
Eichenauer DA, André M, Borchmann P, Collins GP, Doherty I, Eich HT, Federico M, Fossa A, Hartmann S, Hutchings M, Illidge T, Kobe C, Plattel WJ, Specht L, Sureda A, Zaucha JM, Zijlstra JM, Aurer I.   +17 more
europepmc   +1 more source

Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood: A Case Series. [PDF]

Pediatr Blood Cancer
Zarrabi M, Cahaney C, Schwartz LF, Kovach AE, Lin C, Stokke J.   +5 more
europepmc   +1 more source

Etoposide protein binding in cancer patients

Cancer Chemotherapy and Pharmacology, 1995
The protein binding of etoposide was studied in vivo in 36 cancer patients receiving etoposide therapy. Free etoposide was separated from plasma using an ultrafiltration method and the etoposide concentrations (free and total) were measured by high ...
Helena M Earl, Janet Dunn, D J Kerr
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Etoposide phosphate, the water soluble prodrug of etoposide

International Journal of Clinical Pharmacy, 1996
Etoposide (Vepesid) is a widely used drug in a variety of neoplasms. To improve the pharmaceutical characteristics of etoposide, etoposide phosphate (Etopophos, Bristol-Myers Squibb) has been developed as a prodrug. Etoposide phosphate is the phosphate ester derivative of etoposide.
C H W Koks, Beijnen J H
exaly   +4 more sources

Etoposide in leukemia

Cancer, 1991
Etoposide (VP16-213, NSC 141540) induces a complete response (CR) in 15% to 25% of previously treated patients with acute nonlymphocytic leukemia (ANLL) when used as a single agent. Etoposide has been used successfully in combination with cytarabine, daunorubicin, and amsacrine for salvage and consolidation therapies. Previously untreated ANLL patients
J F, Bishop, R, Lowethal, D, Joshua, J P, Matthews, M M, Wolf, I A, Cooper   +5 more
openaire   +2 more sources

Etoposide

Drugs, 2012
Rex N Brogden, Brogden Rex N
exaly   +2 more sources

Oral Etoposide

Drug Intelligence & Clinical Pharmacy, 1988
Etoposide, a semisynthetic derivative of podophyllotoxin, has been commercially available for intravenous use for a number of years, and has been used as part of first-line combination chemotherapy programs for small cell lung cancer (SCLC). It has also been used to treat testicular cancer, non-small cell lung cancer, and a variety of other ...
openaire   +2 more sources

Etoposide see Cisplatin/etoposide

Reactions, 1989
openaire   +2 more sources

Review of Etoposide

American Journal of Health-System Pharmacy, 1983
N C, Phillips, R D, Lauper
openaire   +2 more sources